Tenax Therapeutics

Tenax Therapeutics will present topline results of the phase 3 LEVEL study of TNX‑103 (oral levosimendan) on 29 August 2026 in a late‑breaking session of the ESC in Munich; Prof. Sanjiv Shah will present the data. The study in pulmonary hypertension in heart failure with preserved ejection fraction completed recruitment of more than 230 patients in March 2026; the primary endpoint is the 6‑minute walk distance. A prior re‑assessment found a power of over 90% to detect a difference of 25 meters; Tenax plans a database lock and statistical analysis in the coming weeks. » More on de.investing.com

Tenax Therapeutics is about to release pivotal Phase‑3 data for its cardiopulmonary portfolio. The focus is on the drug candidate TNX-103, with which the company is pursuing therapies for unmet medical needs. Experts rate the program as promising and see substantial upside potential if the study results are positive. » More on finanzen.net

Tenax Therapeutics has appointed Timothy Healey as chief commercial officer with immediate effect. Healey will be responsible for the global commercial strategy and preparation for the potential launch of TNX-103, as well as building commercialization processes and support systems. He joins from Eversana Life Science Services and brings leadership experience from roles at Lantheus, AbbVie and AMAG Pharmaceuticals. Tenax is a clinical-stage pharmaceutical company developing levosimendan for PH-HFpEF; the stock rose significantly last year but has recently shown volatility. » More on de.investing.com